ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2010
Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis.BMC neurology · 2020Pooled it
- Long-term cross sectoral care and case management for people with severe multiple sclerosis and their caregivers - impact on dimensions of life.BMC health services research · 2026Trial
- Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.Journal of neurology · 2014Trial
- "So at least now I know how to deal with things myself, what I can do if it gets really bad again"-experiences with a long-term cross-sectoral advocacy care and case management for severe multiple sclerosis: a qualitative study.BMC health services research · 2024Article
- Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis.Journal of managed care & specialty pharmacy · 2024Observational
- Optimizing HIV PrEP Persistence: Does Your Pharmacy Matter?AIDS and behavior · 2023Article
- Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study.Frontiers in neurology · 2023Article
- Multicenter Study of Nonadherence to Self-Injectable Biologic Therapy in Patients With Inflammatory Bowel Disease: Risk Factors and Outcomes.Gastro hep advances · 2023Article
- Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database.BMC neurology · 2019Article
- One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program.Journal of managed care & specialty pharmacy · 2018Article
- A Comparison of Pharmacy Dispensing Channel Use and Adherence to Specialty Drugs Among Medicare Part D Beneficiaries.Journal of managed care & specialty pharmacy · 2018Article
- Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study.BMC neurology · 2017Article
- An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug.Patient preference and adherence · 2017Article
- The impact of disease characteristics on multiple sclerosis patients' quality of life.Epidemiology and health · 2017Article
- Quantifying Differences in Health Care Consumption for the Management of Multiple Sclerosis Within Privately and Publicly Insured Health Care Programs.Journal of managed care & specialty pharmacy · 2016Article
- Effects of Specialty Pharmacy Care on Health Outcomes in Multiple Sclerosis.American health & drug benefits · 2016Article
- The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review.Patient preference and adherence · 2016Review
- Patient and Physician Perspectives on MSdialog, an Electronic PRO Diary in Multiple Sclerosis.The patient · 2015Article
- Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program.BMC neurology · 2015Observational
- Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis.Patient preference and adherence · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the clinical and economic impact of a specialty care management program among patients with multiple sclerosis.
methodsThis retrospective cohort analysis included patients aged > or =18 years with > or =2 claims of multiple sclerosis diagnosis and > or =1 multiple sclerosis medications from 1 January 2004 to 30 April 2008. The outcome metrics included medication adherence and persistence, multiple sclerosis-related hospitalization, and multiple sclerosis-related cost. Multivariate analyses were performed to adjust for demographics and clinical characteristics.
resultsAmong the 3993 patients identified, 78.3% participated in the program and 21.7% did not. Over 12 months, medication adherence and persistence improved among participants but deteriorated among non-participants (medication possession ratio change: +0.08 vs -0.03, p < 0.001; persistence change: +29.2 days vs -9.2 days, p < 0.001). Multiple sclerosis-related hospitalization decreased from 9.6% to 7.1% for participants, whereas it increased from 10.1% to 12.0% for the non-participant group (p < 0.001). Multiple sclerosis-related medical spending (non-pharmacy) decreased among participants, but it increased among non-participants (mean: -US$264 vs + US$1536, p < 0.001). Total multiple sclerosis-related cost for both groups increased over time (+US$4471 vs +US$4087, p < 0.001).
conclusionsThis program was associated with improved medication adherence and persistence, reduced multiple sclerosis-related hospitalization, and decreased multiple sclerosis-related medical costs. Unfortunately, the cost savings in the medical component did not offset the increased pharmacy expenditures during the 12-month follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.